Towards Genomic Medicine: A Tailored Next-Generation Sequencing Panel for Hydroxyurea Pharmacogenomics in Tanzania-Reference-Cited by-同舟云学术

Towards Genomic Medicine: A Tailored Next-Generation Sequencing Panel for Hydroxyurea Pharmacogenomics in Tanzania

Published:2023-08-25 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Nkya Siana¹,Nzunda Collin¹,Saukiwa Emmanuel¹,Kaywanga Frida¹,Buchard Eliud¹,Solomon David¹,Christopher Heavenlight¹,Ngowi Doreen¹,Johansen Julieth¹,Urio Florence¹,Mgaya Josephine¹,Karim Salman¹,Alimohamed Mohamed Zahir¹,Sangeda Raphael Z.²,Chamba Clara¹,Chimusa Emile R.³,Novelli Enrico⁴,Makani Julie¹

Affiliation:

1. Muhimbili University of Health and Allied Sciences

2. Tanzania Human Genetics Organisation

3. Northumbria University

4. University of Pittsburgh

Abstract

Abstract Pharmacogenomics of hydroxyurea is an important aspect in the management of sickle cell disease (SCD), especially in the era of genomic medicine. Genetic variations in loci associated with HbF induction and drug metabolism are prime targets for hydroxyurea (HU) pharmacogenomics. This study investigated genetic variations in BCL11A, ARG2, HBB, HBG1, WAC, HBG2, HAO2, MYB, SAR1A, KLF10, CYP2C9, CYP2E1 and NOS1 as potential HU pharmacogenomics targets. The panel was designed using the Illumina Design Studio (Illumina, San Diego, CA, USA) and achieved a total coverage of 96% of all genomic targets over a span of 51.6 kilobases (kb). We are reporting a successfully designed Illumina (MiSeq) HU pharmacogenomics custom panel encompassing 51.6 kilobases. The designed panel achieved greater than 1000x amplicon coverage which is which is sufficient for genomic analysis. Therefore, this study provides a valuable tool for research in HU pharmacogenomics, especially in Africa.

Publisher

Research Square Platform LLC

Reference19 articles.

1. How I. use hydroxyurea to treat young patients with sickle cell anemia | Blood | American Society of Hematology. https://ashpublications.org/blood/article/115/26/5300/130853/How-I-use-hydroxyurea-to-treat-young-patients-with. Accessed 8 Jun 2023.

2. Predictors of fetal. hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy | Blood | American Society of Hematology. https://ashpublications.org/blood/article/99/1/10/107215/Predictors-of-fetal-hemoglobin-response-in. Accessed 8 Jun 2023.

3. The effect of prolonged administration of hydroxyurea on morbidity. and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS) | Blood | American Society of Hematology. https://ashpublications.org/blood/article/115/12/2354/125906/The-effect-of-prolonged-administration-of. Accessed 8 Jun 2023.

4. Hydroxyurea for the Treatment of Sickle Cell Anemia;Platt OS;N Engl J Med,2008

5. Emerging science of hydroxyurea therapy for pediatric sickle cell disease;Green NS;Pediatr Res,2014